Skip to main content
. 2022 Jan 28;37(2):266–276. doi: 10.1016/j.virs.2022.01.032

Fig. 4.

Fig. 4

CHIKV E2-E1-LNP mRNA vaccine elicits potent antibody responses better than the sE2-E1 heterodimer subunit vaccine. A Immune strategy of CHIKV E2-E1-LNP. 6-8 weeks-old female C57BL/6 mice were immunized with 10 ​μg E2-E1-LNP or Empty-LNP (n ​= ​6) at weeks 0, 4 and 8 through intramuscular injection. Antibody responses were measured at weeks 2, 6 and 10. B CHIKV specific binding antibodies were detected by ELISA coating with sE2-E1 heterodimer protein. C CHIKV specific neutralizing antibodies were detected by neutralization assay based on CHIKV pseudoviral system. D Antigen specific binding antibodies of the subunit vaccine or mRNA vaccine immunized mice after the 3rd immunization were captured with sE2-E1 protein using V5-pAb pre-coating ELISA plate. E CHIKV neutralizing antibodies detection of serum samples from sE2-E1 protein or E2-E1-LNP immunized mice after the 3rd immunization. Statistical differences were determined using t-test (∗P ​< ​0.05; ∗∗P ​< ​0.01; ∗∗∗P ​< ​0.001; ∗∗∗∗P ​< ​0.0001).